Yong Guo

TL;DR: A disulfide bond is introduced between the C-terminal region of gp120 and the immunodominant segment of the gp41 ectodomain, producing a properly folded envelope glycoprotein complex which has antigenic properties which resemble those of the virion-associated complex.

TL;DR: The data support expanded use of resistance testing in the setting of primary HIV-1 infection, and clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical triple combination antiretroviral therapy, provides additional virological and immunological benefit.

TL;DR: CCR2-V64I is indeed protective against disease progression and is shown to be in complete linkage disequilibrium with a point mutation in the CCR5 regulatory region.

TL;DR: Surprisingly, there was no correlation between the ability of a MAb to inhibit HIV-1 fusion-entry and its ability to inhibit either the binding of a gp120-soluble CD4 complex to CCR5 or CC-chemokine activity.

TL;DR: In cases with apparent complete HIV-1 suppression by HAART, viral rebound after cessation of therapy could have originated from the activation of virus from the latent reservoir, and in patients with incomplete suppression by chemotherapy, the viral rebound is likely triggered by ongoing, low-level replication of HIV- 1, perhaps occurring in lymphoid tissues.